OverviewSuggest Edit

Biostage is a biotechnology company developing bio engineered organ implants based on its novel Cellframe technology. The Company's Cellframe technology is comprised of a biocompatible scaffold seeded with the patient’s own stem cells. Biostage is pursuing the Cellspan esophageal implant as its first product candidate to address esophageal atresia and esophageal cancer and is also developing its technology’s applications to address conditions of the bronchus and trachea. 

TypePublic
Founded2012
HQHolliston, US
Websitebiostage.com
Employee Ratings0

Latest Updates

Employees (est.) (Feb 2019)14(-48%)
Revenue (FY, 2016)$82 K(-30%)

Key People/Management at Biostage

Jim McGorry

Jim McGorry

CEO
Hong Yu

Hong Yu

President
Tom McNaughton

Tom McNaughton

CFO
William Fodor

William Fodor

Chief Scientific Officer
Shunfu Hu

Shunfu Hu

Director of Business Development
Sumati Sundaram

Sumati Sundaram

Director of Cell Biology
Show more

Biostage Office Locations

Biostage has an office in Holliston
Holliston, US (HQ)
84 October Hill Rd
Show all (1)

Biostage Financials and Metrics

Biostage Revenue

Biostage's revenue was reported to be $82 k in FY, 2016 which is a 30.5% decrease from the previous period.
USD

Net income (Q1, 2019)

(1.9m)

EBIT (Q1, 2019)

(2.0m)

Market capitalization (8-Oct-2018)

11.1m

Cash (31-Mar-2019)

1.1m
Biostage's current market capitalization is $11.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

22.0k93.0k118.0k82.0k

Revenue growth, %

323%27%(31%)

Cost of goods sold

11.0k48.0k139.0k116.0k

Gross profit

11.0k45.0k(21.0k)(34.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2019

Revenue

23.0k23.0k2.0k73.0k37.0k28.0k26.0k

Cost of goods sold

12.0k12.0k1.0k37.0k18.0k44.0k13.0k

Gross profit

11.0k11.0k1.0k36.0k19.0k(16.0k)13.0k

Gross profit Margin, %

48%48%50%49%51%(57%)50%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.0m5.3m7.5m2.9m4.0m1.3m

Accounts Receivable

21.0k42.0k

Inventories

38.0k75.0k

Current Assets

14.5m5.8m7.9m3.5m4.4m2.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

12.6m10.1m7.7m12.2m10.1m8.2m4.8m8.1m6.0m6.6m3.4m1.3m2.8m5.8m3.5m1.1m

Accounts Receivable

81.0k59.0k18.0k40.0k66.0k37.0k

Inventories

129.0k146.0k157.0k144.0k79.0k47.0k41.0k

Current Assets

33.0k13.1m10.6m8.1m12.6m10.6m8.5m5.4m8.3m6.2m6.9m3.7m1.7m3.3m6.2m3.9m1.7m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(8.8m)(11.1m)(11.7m)(11.6m)(7.5m)

Depreciation and Amortization

158.0k363.0k478.0k454.0k413.0k261.0k

Inventories

(38.0k)(169.0k)75.0k

Accounts Payable

65.0k126.0k(13.0k)472.0k(43.0k)(763.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(5.5m)(8.2m)(2.6m)(7.1m)(9.4m)(2.5m)(5.2m)(8.2m)(3.8m)(7.4m)(10.7m)(1.5m)(3.6m)(5.7m)(1.9m)

Depreciation and Amortization

123.0k56.0k151.0k256.0k112.0k226.0k347.0k111.0k224.0k340.0k121.0k236.0k334.0k63.0k128.0k194.0k61.0k

Inventories

(91.0k)(108.0k)(119.0k)(5.0k)(4.0k)28.0k34.0k

Accounts Payable

(53.0k)162.0k71.0k10.0k(109.0k)(83.0k)(150.0k)(137.0k)230.0k418.0k(249.0k)(275.0k)246.0k(698.0k)(759.0k)(721.0k)127.0k
USDY, 2019

Financial Leverage

1.7 x
Show all financial metrics

Biostage Online and Social Media Presence

Embed Graph

Biostage News and Updates

Biostage Reports 2018 Third Quarter Financial Results

HOLLISTON, Mass., Nov. 8, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financial results for ...

Ms. Ting Li Appointed to Biostage Board of Directors

HOLLISTON, Mass., Nov. 7, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus, and trachea, today announced appointing Ms. Ting Li to its Board of Directors after ...

Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia

HOLLISTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has been awarded $1.1 million from Phase II of its...

Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations

HOLLISTON, Mass., Nov. 2, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the three ...

Biostage to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Operations

HOLLISTON, Mass., Aug. 9, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the three ...

Biostage Blogs

Biostage Reports First Quarter 2019 Financial Results

- Preparing to file first IND in Q3 2019

Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update

- Conference Call with Live Audio Webcast on Tuesday May 14th at 9:00 AM ET -

Biostage Reports 2018 Financial Results

- Pre-clinical and human compassionate use clinical evidence support IND filing mid-year 2019

Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update

- Conference Call with Live Audio Webcast on Thursday March 28th at 9:00 AM ET -
Show more

Biostage Frequently Asked Questions

  • When was Biostage founded?

    Biostage was founded in 2012.

  • Who are Biostage key executives?

    Biostage's key executives are Jim McGorry, Hong Yu and Tom McNaughton.

  • How many employees does Biostage have?

    Biostage has 14 employees.

  • Who are Biostage competitors?

    Competitors of Biostage include Biovotion, Ceterix Orthopaedics and RTI Surgical.

  • Where is Biostage headquarters?

    Biostage headquarters is located at 84 October Hill Rd, Holliston.

  • Where are Biostage offices?

    Biostage has an office in Holliston.

  • How many offices does Biostage have?

    Biostage has 1 office.